Eli Lilly: new analyses show diabetes drug reduces risks.
(CercleFinance.com) - New analyses of a trial showed that Jardiance tablets reduced the risk of cardiovascular death in adults with type-2 diabetes and established cardiovascular disease, Eli Lilly said on Tuesday.
In all four blood sugar level groups at study start, patients receiving Jardiance demonstrated a reduction in the risk of cardiovascular death compared with placebo, the US drugmaker said.
Jardiance is the first and only oral type-2 diabetes medicine that has been approved to reduce the risk of cardiovascular death in adults with type-2 diabetes and established cardiovascular disease.
These results from post-hoc analyses were presented by Boehringer Ingelheim and Eli Lilly at the annual meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.
The multicenter trial involved over 7,000 patients from 42 countries with type-2 diabetes and established cardiovascular disease.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
In all four blood sugar level groups at study start, patients receiving Jardiance demonstrated a reduction in the risk of cardiovascular death compared with placebo, the US drugmaker said.
Jardiance is the first and only oral type-2 diabetes medicine that has been approved to reduce the risk of cardiovascular death in adults with type-2 diabetes and established cardiovascular disease.
These results from post-hoc analyses were presented by Boehringer Ingelheim and Eli Lilly at the annual meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.
The multicenter trial involved over 7,000 patients from 42 countries with type-2 diabetes and established cardiovascular disease.
Copyright (c) 2017 CercleFinance.com. All rights reserved.